Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies

Bibliography

• Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010;7:3572-88
   PubMed Web of Science ®Google Scholar
• Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2010;7(1 Pt 2):314-26
   PubMed Web of Science ®Google Scholar
• Costa C, Virag R. The endothelial-erectile dysfunction connection: an essential update. J Sex Med 2009;6:2390-404
   PubMed Web of Science ®Google Scholar
• Müller A, Mulhall JP. Cardiovascular disease, metabolic syndrome and erectile dysfunction. Curr Opin Urol 2006;16:435-43
   PubMed Web of Science ®Google Scholar
• Nappi R, Salonia A, Traish AM, et al. Clinical biologic pathophysiologies of women’s sexual dysfunction. J Sex Med 2005;2:4-25
   PubMed Web of Science ®Google Scholar
• Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 2011;63:811-59
   PubMed Web of Science ®Google Scholar
• Porst H. An overview of pharmacotherapy in premature ejaculation. J Sex Med 2011;8(Suppl 4):335-41
   PubMedGoogle Scholar
• Fooladi E, Davis SR. An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother 2012;13:2131-42
   PubMed Web of Science ®Google Scholar
• King SH, Mayorov AV, Balse-Srinivasan P, et al. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem 2007;7:1098-106
   PubMed Web of Science ®Google Scholar
• Shadiack AM, Sharma SD, Earle DC, et al. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem 2007;7:1137-44
   PubMed Web of Science ®Google Scholar
• Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab 2003;284:E468-74
   PubMed Web of Science ®Google Scholar
• Voisey J, Carroll L, van Daal A. Melanocortins and their receptors and antagonists. Curr Drug Targets 2003;4:586-97
   PubMed Web of Science ®Google Scholar
• de Wied D. Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. Eur J Pharmacol 1999;375:1-11
   PubMed Web of Science ®Google Scholar
• Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 2005;26:1687-9
   PubMed Web of Science ®Google Scholar
• Mountjoy KG. Distribution and function of melanocortin receptors within the brain Adv Exp Med Biol 2010;681:29-48
   Google Scholar
• Ständer S, Böhm M, Brzoska T, et al. Expression of melanocortin-1 receptor in normal, malformed and neoplastic skin glands and hair follicles. Exp Dermatol 2002;11:42-51
   PubMed Web of Science ®Google Scholar
• Larsson LI. Distribution of ACTH-like immunoreactivity in rat brain and gastrointestinal tract. Histochemistry 1978;55:225-33
   PubMedGoogle Scholar
• van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002;99:11381-6
   PubMed Web of Science ®Google Scholar
• Gelez H, Poirier S, Facchinetti P, et al. Neuroanatomical distribution of the melanocortin-4 receptors in male and female rodent brain. J Chem Neuroanat 2010;40:310-24
   PubMed Web of Science ®Google Scholar
• Gelez H, Poirier S, Facchinetti P, et al. Neuroanatomical evidence for a role of central melanocortin-4 receptors and oxytocin in the efferent control of the rodent clitoris and vagina. J Sex Med 2010;7:2056-67
   PubMed Web of Science ®Google Scholar
• Nocetto C, Cragnolini AB, Schiöth HB, Scimonelli TN. Evidence that the effect of melanocortins on female sexual behavior in preoptic area is mediated by the MC3 receptor; participation of nitric oxide. Behav Brain Res 2004;153:537-41
   PubMed Web of Science ®Google Scholar
• Shadiack AM, Sharma SD, Earle DC, et al. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem 2007;7:1137-44
   PubMed Web of Science ®Google Scholar
• Pfaus JG, Shadiack A, Van Soest T, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA 2004;101:10201-4
   PubMed Web of Science ®Google Scholar
• Aughton KL, Hamilton-Smith K, Gupta J, et al. Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro. Br J Pharmacol 2008;155:236-43
   PubMed Web of Science ®Google Scholar
• Giuliano F, Clément P, Droupy S, et al. Melanotan-II: investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience 2006;138:293-301
   PubMed Web of Science ®Google Scholar
• Wessells H, Hruby VJ, Hackett J, et al. MT-II induces penile erection via brain and spinal mechanisms. Ann NY Acad Sci 2003;994:90-5
   PubMed Web of Science ®Google Scholar
• Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1998;160:389-93
   PubMed Web of Science ®Google Scholar
• Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res 2000;12(Suppl 4):S74-9
   PubMed Web of Science ®Google Scholar
• Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004;16:51-9
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Gittelman M, Zinner N, et al. Randomized, double-blind, placebo-controlled, at-home study to evaluate the efficacy and safety of intranasal bremelanotide in men with erectile dysfunction with and without diabetes mellitus [abstract]. J Sex Med 2006;4(Suppl 2):117. Presented at the 9th Congress of the European Society for Sexual Medicine; 3 – 6 December 2006; Vienna, Austria
   Google Scholar
• Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004;16:135-42
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008;179:1066-71
   PubMed Web of Science ®Google Scholar
• Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction resultts in enhanced erectile response. Urology 2005;65:755-9
   PubMed Web of Science ®Google Scholar
• Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006;3:628-38
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med 2008;5:887-97
   PubMed Web of Science ®Google Scholar
• Krychman M, Edelson J, Jordan R, Rosen R. Improvement in sexual function as measured by the female sexual function index in premenopausal women during a 12-week placebo-controlled dose-ranging study of self administrated subcutaneous bremelanotide for female sexual dysfunctions [abstract]. J Sex Med 2014. 11(Suppl 1):18. Presented at the 16th Congress of the European Society for Sexual Medicine; 29-January – 1-Febuary 2014; Istanbul, Turkey
   Google Scholar